CD274 and neoplasm: Notably, it has also been reported that the loss of YTHDF1 strengthens the cross-presentation of tumor antigens and the cross-priming of CD8 + T cells, and enhances the blocking effect of the programmed cell death 1 ligand 1 (PD-L1) checkpoint in vivo, suggesting that YTHDF1 functions as a potential therapeutic target [17].